Dear Editor, Chimeric Antigen Receptor T cell (CAR-T) therapy induces heterogenous depth of response and response kinetics in relapsed/refractory multiple myeloma (RRMM). E.g., in the KARMMA-1 trial, the median time to first response was 1 month (range 0.5–8.8), while the median time to complete response or better was also variable (median 2.8 months, range 1–11.8) [1]. This post-infusion disease behavior may not be fully captured by pre-infusion risk-stratification approaches alone [2,3,4,5,6].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Diana
Contact Diana, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack